Last reviewed · How we verify

Moxifloxacin Hydrochloride, Ophthalmic

Laboratorios Sophia S.A de C.V. · Phase 3 active Small molecule

Moxifloxacin Hydrochloride, Ophthalmic is a Fluoroquinolone antibiotic Small molecule drug developed by Laboratorios Sophia S.A de C.V.. It is currently in Phase 3 development for Bacterial conjunctivitis, Bacterial keratitis, Bacterial corneal ulcer.

Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible microorganisms.

Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible microorganisms. Used for Bacterial conjunctivitis, Bacterial keratitis, Bacterial corneal ulcer.

At a glance

Generic nameMoxifloxacin Hydrochloride, Ophthalmic
SponsorLaboratorios Sophia S.A de C.V.
Drug classFluoroquinolone antibiotic
TargetDNA gyrase; Topoisomerase IV
ModalitySmall molecule
Therapeutic areaOphthalmology / Infectious Disease
PhasePhase 3

Mechanism of action

As a broad-spectrum fluoroquinolone, moxifloxacin works by binding to and inhibiting bacterial DNA gyrase (in gram-negative bacteria) and topoisomerase IV (in gram-positive bacteria), enzymes essential for DNA replication and repair. This dual mechanism results in rapid bactericidal activity against a wide range of gram-positive and gram-negative bacteria, as well as atypical organisms. When formulated as an ophthalmic solution, it achieves high local concentrations in ocular tissues to treat bacterial infections of the eye.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Moxifloxacin Hydrochloride, Ophthalmic

What is Moxifloxacin Hydrochloride, Ophthalmic?

Moxifloxacin Hydrochloride, Ophthalmic is a Fluoroquinolone antibiotic drug developed by Laboratorios Sophia S.A de C.V., indicated for Bacterial conjunctivitis, Bacterial keratitis, Bacterial corneal ulcer.

How does Moxifloxacin Hydrochloride, Ophthalmic work?

Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible microorganisms.

What is Moxifloxacin Hydrochloride, Ophthalmic used for?

Moxifloxacin Hydrochloride, Ophthalmic is indicated for Bacterial conjunctivitis, Bacterial keratitis, Bacterial corneal ulcer, Post-operative ocular infections.

Who makes Moxifloxacin Hydrochloride, Ophthalmic?

Moxifloxacin Hydrochloride, Ophthalmic is developed by Laboratorios Sophia S.A de C.V. (see full Laboratorios Sophia S.A de C.V. pipeline at /company/laboratorios-sophia-s-a-de-c-v).

What drug class is Moxifloxacin Hydrochloride, Ophthalmic in?

Moxifloxacin Hydrochloride, Ophthalmic belongs to the Fluoroquinolone antibiotic class. See all Fluoroquinolone antibiotic drugs at /class/fluoroquinolone-antibiotic.

What development phase is Moxifloxacin Hydrochloride, Ophthalmic in?

Moxifloxacin Hydrochloride, Ophthalmic is in Phase 3.

What are the side effects of Moxifloxacin Hydrochloride, Ophthalmic?

Common side effects of Moxifloxacin Hydrochloride, Ophthalmic include Conjunctival irritation, Eye discomfort, Ocular hyperemia, Taste perversion, Corneal staining.

What does Moxifloxacin Hydrochloride, Ophthalmic target?

Moxifloxacin Hydrochloride, Ophthalmic targets DNA gyrase; Topoisomerase IV and is a Fluoroquinolone antibiotic.

Related